• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study.

作者信息

Kataoka Y, Ebi N, Fujimoto D, Hara S, Hirano K, Narabayashi T, Tanaka T, Tomii K, Yoshioka H

机构信息

Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki.

Department of Respiratory Medicine, Iizuka Hospital, Iizuka.

出版信息

Ann Oncol. 2017 Jun 1;28(6):1402. doi: 10.1093/annonc/mdx114.

DOI:10.1093/annonc/mdx114
PMID:28368440
Abstract
摘要

相似文献

1
Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study.
Ann Oncol. 2017 Jun 1;28(6):1402. doi: 10.1093/annonc/mdx114.
2
Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer.在接受纳武单抗单药治疗之前立即接受的治疗反应，可能预测非小细胞肺癌患者对纳武单抗的临床反应。
Int J Clin Oncol. 2017 Aug;22(4):690-697. doi: 10.1007/s10147-017-1118-x. Epub 2017 Apr 5.
3
Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med. 2016 Feb 4;374(5):493. doi: 10.1056/NEJMc1514790.
4
Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗用于非鳞状非小细胞肺癌
N Engl J Med. 2016 Feb 4;374(5):492-3. doi: 10.1056/NEJMc1514790.
5
Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.纳武单抗用于非鳞状非小细胞肺癌
N Engl J Med. 2016 Feb 4;374(5):493-4. doi: 10.1056/NEJMc1514790.
6
Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence.接受过放疗区域复发的患者在使用纳武单抗治疗后发生肿瘤flare的风险。
Med Oncol. 2017 Mar;34(3):34. doi: 10.1007/s12032-017-0895-4. Epub 2017 Jan 30.
7
Case series of pleomorphic carcinomas of the lung treated with nivolumab.肺多形性癌的纳武利尤单抗治疗病例系列。
Thorac Cancer. 2017 Nov;8(6):724-728. doi: 10.1111/1759-7714.12505. Epub 2017 Sep 7.
8
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-Small Cell Lung Cancer.纳武利尤单抗增强晚期非小细胞肺癌照射野的炎症反应。
J Thorac Oncol. 2017 Nov;12(11):1733-1736. doi: 10.1016/j.jtho.2017.07.025. Epub 2017 Jul 31.
9
Nivolumab for advanced squamous cell lung cancer: what are the next steps?纳武单抗用于晚期肺鳞状细胞癌：后续步骤是什么？
Lancet Oncol. 2015 Mar;16(3):234-5. doi: 10.1016/S1470-2045(15)70074-4. Epub 2015 Feb 20.
10
Nivolumab: a review in advanced squamous non-small cell lung cancer.纳武利尤单抗：晚期鳞状非小细胞肺癌的研究进展。
Drugs. 2015 Nov;75(16):1925-34. doi: 10.1007/s40265-015-0492-9.

引用本文的文献

1
Immunotherapy combined with radiotherapy for advanced non-small cell lung cancer: Current status and challenge (Review).免疫疗法联合放疗治疗晚期非小细胞肺癌：现状与挑战（综述）
Oncol Lett. 2025 Aug 4;30(4):469. doi: 10.3892/ol.2025.15215. eCollection 2025 Oct.
2
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415).重新审视在PD-1阻断基础上联合姑息性放疗用于非小细胞肺癌的治疗：FORCE II期试验（AIO/YMO-TRK-0415）的结果
Clin Exp Metastasis. 2025 Jul 24;42(5):42. doi: 10.1007/s10585-025-10358-x.
3
Efficacy and safety of immunoradiotherapy for advanced non-small cell lung cancer: a retrospective comparative cohort study.
免疫放射疗法治疗晚期非小细胞肺癌的疗效与安全性：一项回顾性比较队列研究
J Thorac Dis. 2023 Jun 30;15(6):3182-3196. doi: 10.21037/jtd-22-1685. Epub 2023 May 15.
4
Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.免疫检查点抑制剂联合或不联合放疗用于转移性非小细胞肺癌的疗效与安全性：一项系统评价和荟萃分析
Front Pharmacol. 2023 Jan 24;14:1064227. doi: 10.3389/fphar.2023.1064227. eCollection 2023.
5
Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.癌症中PD-1/PD-L1抑制剂预测生物标志物的比较分析：进展与挑战
Cancers (Basel). 2021 Dec 27;14(1):109. doi: 10.3390/cancers14010109.
6
Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy.既往放疗和免疫治疗相关不良反应在接受抗PD-1/L1治疗的晚期非小细胞肺癌患者中的预测作用
J Clin Med. 2021 Aug 21;10(16):3719. doi: 10.3390/jcm10163719.
7
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.在 durvalumab 获批前局部晚期非小细胞肺癌患者同步放化疗的现状和进展。
Thorac Cancer. 2020 Apr;11(4):1005-1014. doi: 10.1111/1759-7714.13357. Epub 2020 Feb 14.
8
A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.一例伴有EGFR突变及周围PD-L1阳性肿瘤相关巨噬细胞的PD-L1阴性肺腺癌患者对纳武单抗的长期反应
Intern Med. 2019 Oct 15;58(20):3033-3037. doi: 10.2169/internalmedicine.2875-19. Epub 2019 Jul 10.
9
Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.联合 PD-1 通路抑制和放射治疗非小细胞肺癌的安全性：来自 GFPC 的多中心回顾性研究。
Cancer Med. 2018 Nov;7(11):5505-5513. doi: 10.1002/cam4.1825. Epub 2018 Oct 11.